Clinical Trial Update: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing IV fosnetupitant/palonosetron to oral netupitant/palonosetron for prevention of chemotherapy-induced nausea and vomiting in women with b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• IV fosnetupitant/palonosetron (fosnetupitant/palonosetron)
• oral netupitant/palonosetron (netupitant/palonosetron)

Snippet

Sponsor: Helsinn Healthcare SA | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2020-04-15